JPM vs LYRA · P/E 14, rev $57.35B vs rev $1.5M
JPMorgan Chase & Co (JPM) versus Lyra Therapeutics Inc (LYRA) — a side-by-side from cached financials, not a winner call.
JPMorgan Chase & Co (JPM) is a banks - diversified company listed on US. It is led by Jamie Dimon.
Lyra Therapeutics Inc (LYRA) is a biotechnology company listed on US.
Latest reported JPM revenue for 2026-06-30 was $57.35B. Net income was $21.16B. Revenue was up 15.1% from 2026-03-31 to 2026-06-30. JPM currently screens at market cap $805.69B and trailing P/E 14.2.
Latest reported LYRA revenue for 2024-12-31 was $1.5M. Net income was -$93.4M. Revenue was down 1.5% from 2023-12-31 to 2024-12-31. LYRA currently screens at market cap $14.4M.
JPM currently screens at market cap $805.69B and trailing P/E 14.2. LYRA currently screens at market cap $14.4M.
Not investment advice. Open the JPM and LYRA stock pages for the full models.
Not investment advice.